Natixis’s Mirum Pharmaceuticals MIRM Stock Holding History

Natixis’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$832K	Buy	+7,107	New	+$714K	﹤0.01%	772

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Natixis's MIRM Position: Q2 2026 in Review

Natixis opened a new position in Mirum Pharmaceuticals (MIRM) in Q2 2026: 7,107 shares worth $832K. The stake represents ﹤0.01% of the portfolio and ranks #772 among its holdings.

327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

Natixis held 7,107 shares of Mirum Pharmaceuticals worth $832K as of Q2 2026.
Mirum Pharmaceuticals was a new Natixis position in Q2 2026.
Mirum Pharmaceuticals made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #772 holding.
327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.